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Background/aim: Macrothrombocytopenia is an autosomal-dominant disorder characterized by increased platelet size and a decreased
number of circulating platelets. The membrane skeleton and the link between actin filaments of the skeleton and microtubules, which
consist of alpha and beta tubulin [including the tubulin beta-1 chain (TUBB1)] heterodimers, are important for normal platelet
morphology, and defects in these systems are associated with macrothrombocytopenia.
Materials and methods: In this study, we sequenced the exons of the TUBB1 gene using DNA isolated from the peripheral blood samples
of healthy controls (n = 47) and patients with macrothrombocytopenia (n = 37) from Turkey. The TUBB1 expression levels in fractioned
blood samples from patients and healthy controls were analyzed by RT-qPCR and Western blot. Microtubule organization of the platelets
in the peripheral blood smears of patients, and in mutant TUBB1-transfected HeLa cells, were analyzed by immunofluorescence staining.
Results: A new TUBB1 c.803G>T (p.T178T) variant was detected in all of the control and patient samples. Importantly, we found 3
new heterozygous TUBB1 variants predicting amino acid substitutions: G146R (in 1 patient), E123Q (in 1 patient), and T274M (in 4
patients); the latter variant was associated with milder thrombocytopenia in cancer patients treated with paclitaxel. Ectopic expression
of TUBB1 T274M/R307H variant in HeLa cells resulted in irregular microtubule organization.
Conclusion: Further clinical and functional studies of the newly identified TUBB1 variants may offer important insights into their
pathogenicity in macrothrombocytopenia.
Key words: TUBB1, macrothrombocytopenia, MYH9, platelets

1. Introduction
Although the frequency of rare bleeding disorders
ranges from 1 in 500,000 to 1 in 2 million, in countries
with a high rate of consanguineous marriages they occur
more frequently and constitute an important health
problem [1]. Macrothrombocytopenia is a congenital
autosomal-dominant blood disorder characterized
by increased platelet size and a decreased number of
circulating platelets [2]. Macrothrombocytopenia is
classified within the genetically heterogeneous group
of rare disorders. There are more than 12 genes that are
thought to be associated with macrothrombocytopenia
including MYH9 (MIM155100), ACTN1 (MIM615193)
GP1A (MIM606672), GP9 (MIM173515), FL1
(MIM193067), FLNA (MIM3000017), ITG2A/ITGB3
(MIM 607759/173470), GATA1 (MIM305371), NBEAL2

(MIM614169), and VWF (MIM613160). Although the
mutations in these genes have been associated with
macrothrombocytopenia, an understanding of their role
in the development of the disease remains elusive [3,4].
The membrane skeleton, and the link between actin
filaments of the skeleton and microtubules, maintain
normal platelet morphology [5], which is critical for
macrothrombocytopenia given that patients display
defects in the size and structure of platelets. Alpha- and
beta-tubulin heterodimers are the key components of
these structures [6]. Among the beta-tubulin isoforms,
expression of TUBB1 is restricted to the megakaryocytes
and platelets, and its expression is induced during the
differentiation of megakaryocytes, suggesting a role in
proplatelet production and platelet release [7]. TUBB1, a
7401 base-pair gene, is located on human chromosome
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20q13.3 and consists of 4 exons which encode 451 amino
acids [6]. It functions in the building of the marginal
band in platelets, a unique cytoskeleton structure that is
composed of bundles of circumferential microtubules
that support the maintenance of the shape and function
of platelets [8,9]. Sequencing studies in patients with
macrothrombocytopenia described several TUBB1 variants
that are mainly found in exon 4, which is the longest exon
of the gene. Whether the same variants exist with similar
frequency and whether there are additional undescribed
TUBB1 variants in Turkey is not known. Here, we sequenced
the TUBB1 gene in patients with macrothrombocytopenia
and in healthy controls from Turkey using exon-specific
PCR. Due to sample limitations, we were only able to
analyze TUBB1 mRNA expression and platelet structure
in a sample of one patient carrying the missense variants
of TUBB1 (p.T274M/p.R307H). We also generated a Flagtagged TUBB1 variant (p.T274M/p.R307H) by using the
cDNA of the same patient. The microtubule structure of
HeLa cells expressing this ectopic Flag-tagged mutant
TUBB1 was analyzed using confocal microscopy after IC
staining with ACTIN and TUBB1 (or Flag) antibodies.
2. Materials and methods
2.1. Blood sampling, DNA isolation, and sequencing
Written, informed consent for genetic analysis was obtained
from the patients. Approval was also obtained from the
Okan University Clinical Research Ethics Committee
(24.09.2014; no: 09.2014.50) in order to comply with the
ethical rules of the study. Blood samples of the patients (n
= 37) and healthy controls (n = 47) were obtained from
various hematology clinics in Turkey. Platelet counts of all
patients and healthy controls were evaluated. Patients were
asymptomatic at the time of admission, and peripheral
blood sampling revealed macrothrombocytopenia. Platelet
counts of 150–450 × 103/uL and MPV values of 7.5 fL–
11.5 fL were accepted as control in the study. These were
then subjected to molecular genetic analysis. The MYH9related disorder was previously thought to be four separate
disorders; May–Hegglin anomaly, Epstein syndrome,
Fechtner syndrome, and Sebastian syndrome. All of
these disorders involved thrombocytopenia and enlarged
platelets and were distinguished by some combination of
hearing loss, renal disease, and cataracts. Nonhematological
findings (renal disease, cataracts, hearing loss, etc.) were
evaluated by the relevant clinics.
The PCR reactions were performed using 25 ng DNA
and GoTaq green master mix reagent in a 20 µL PCR volume
(Promega, Wisconsin, USA). Primers were designed using
an online tool from the Santa Cruz Genome Browser1
(Table 1). Sequences were analyzed with the Finch TV
program.
1

2.2. RNA isolation and RT-qPCR
Platelet-rich plasma (PRP) and peripheral blood
mononuclear cells (PBMC) were isolated from the sample
of patient #7 (Tables 2 and 3), who carries heterozygous
TUBB1 variants (p.T274M/p.R307H) in cis-position,
and healthy volunteers (n = 4; pooled samples) using
Lymphoprep density gradient media (Axis–Shield,
Dundee, UK), according to manufacturer instructions.
Total RNA was extracted using TriPure isolation reagent
(Roche, Penzberg, Germany), and 1 µg of RNA was reverse
transcribed to cDNA using the High-Capacity cDNA
reverse transcription kit (Applied Biosytems, California,
USA), following manufacturer instructions. The TUBB1
and ACTB (housekeeping gene) mRNA levels in the
PRP and PBMC of the patient and control samples were
analyzed by RT-qPCR using Taqman primer-probe sets in
triplicate (TUBB1 hs00258236_m1; ACTIN hs01060665_
g1) (Applied Biosystems, California, USA). The ΔΔCt
method was used to calculate relative gene expression.
2.3. TUBB1 cloning and transfection
The C-terminus Flag-tagged wild type and mutant
(p.T274M/p.R307H) full-length TUBB1 cDNA was
synthesized from the PBMC of patient #7 and cloned into
p3XFLAG-CMV-14 expression vector (Sigma–Aldrich,
Missouri, USA) using the following primers: forward
5’-TACGGCGGCCGCGATGCGTGAAATTGTCCATAT
TCA-3’ and reverse 5’-TACGGGTACCATGTCCCTTATC
TTCTGG-3’. The integrity of the constructs was confirmed
by sequencing. HeLa cells were transiently transfected
with these vectors using jetPRIME transfection reagent
(Polyplus Transfection, Illkirch, France), following
manufacturer instructions.
2.4. Immunofluorescence staining
For immunofluorescence (IF) staining, peripheral blood
smears or the transfected HeLa cells that were seeded on
the chamber slides were fixed with absolute methanol
at –20 °C for 15 min. After washing with PBS-T (0.1%
Triton-X-100), slides were incubated in blocking/
permeabilization solution (2% skim milk in PBS-T) at
room temperature for 1 h. Transfected HeLa cells were
incubated with mouse antihuman α-TUBULIN antibody
(Santa Cruz, sc-5286; 1:100 dilution, Texas, USA) and
rabbit antihuman Flag antibody (Sigma–Aldrich, F7425;
1:100 dilution). Slides of fixed blood smears were incubated
with mouse antihuman TUBB1 antibody (OriGene,
TA506654, 1:150 dilution, Maryland, USA) and rabbit
antihuman α-TUBULIN antibody (Cell Signaling, 2125;
1:100 dilution, Massachusetts, USA). After washing, slides
were incubated with corresponding anti-IgG antibodies
with Alexa-488 (Cell Signaling, 4412; 1:500 dilution)
or Alexa-555 fluorophore (Cell Signaling, 4409; 1:500

Santa Cruz Genomic Institute. Genome Browser. Website https://genome.ucsc.edu/
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Table 1. Primers that were used in the PCR reactions and sequencing of TUBB1.
Exons

Forward primer

Reverse primer

Amplicon
(bp)

1

CATACCACGGTCACTAGGGC

AAAGCCCAAAGGCATTGTC

587

2

GGAAACAGGCTTGGGAATG

CATTTCCATCTCCTGGGC

282

3

TTTGGACCAGTATCACAAAGTTC

AAAAGAGAAACCAGCAGGGG

295

4–1

GCATTCGATCTAGCAAATTAGG

ATCGAACATCTGCTGGGTG

766

4–2

TACCCTGAAGCTGACGACAC

GCTGCAGGAGAAACACTCATC

789

4–3

AACGAATTTGGGGAAGCTG

GAAAGCAGGATGCCAGTCAG

608

4–4

GGATTTGCAGGGAGCCAC

TTCCTGCATTTGAATGGTTG

623

4–5

TTTCATTCAGTCATCACCCC

TTGGTATGTATTTTAGTTATTTCCTCG

604

4–6

GGGTTCTCATCTCTTGATTTGC

CGAAAGAGTAGGATGGTGAGATG

620

Table 2. The summary of variants found in exon-4 of TUBB1 gene in Turkish population.
Exon-4 specific
primer pairs
Exon 4.1

Alteration type
Silent

Amino acid
change

Nucleotide change

T178T

c. 803G > T
All Patients (n=37) and controls (n=47)

Exon 4.1

Missense

G146R

c.705 G > A
Patient #36

Exon 4.1

Missense

E123Q

c.636 C > G
Patient #17

Exon 4.1

Silent

H122H

635 C > T
Patient # 30

Exon 4.2

Missense

T274M

821 C > T
Patients #2,3,7,37

Exon 4.2

Known polymorphism in
macrotrombocytopenia

R307H

920 G > A
19 out of 37 Patients 13 out of 47 controls

dilution) at room temperature for 1 h. Slides were mounted
with DAPI solution (1 µg/10 mL prepared in ddH2O) for
nuclei staining. Stained cells were visualized under LSM
880 laser scanning confocal microscope (Zeiss, Göttingen,
Germany).
2.5. Western blot analysis
Whole protein lysate was isolated using RIPA buffer [150
mMNaCl, 50 mMTris-HCl (pH = 8), 1% NP40, 0.5%
sodium deoxycholate, 0.1% SDS] completed with 100X
protease/phosphatase inhibitor cocktail (Thermo Fisher,
Massachusetts, USA), and protein concentration was
measured by BCA protein assay kit (Thermo Fisher). Each
lysate from different samples was separated by using MiniPROTEAN TGX 10% precast gel (Bio-Rad, California,
USA) and transferred to nitrocellulose membrane using
Trans-Blot Turbo transfer system (Bio-Rad). Membranes
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were blocked with 5% BSA (Sigma–Aldrich) in TBS-T and
then incubated with a mouse antihuman TUBB1 antibody
(OriGene, TA506654; 1:3000 dilution) at 4 °C overnight,
an anti-Flag HRP antibody (Abcam, ab49763; 1:1000
dilution, Cambridge, UK) at room temperature for 1 h, a
rabbit antihuman GAPDH antibody (Cell Signaling, 5174;
3:10000 dilution) at room temperature for 1 h, or a rabbit
antihuman β-actin antibody (Cell Signaling, 8457; 1:1000
dilution) at room temperature for 1 h. Upon washing with
TBS-T, membranes were incubated with compatible HRPconjugated antimouse IgG (Cell Signaling, 7076; 1:5000
dilution) or antirabbit IgG (Cell Signaling, 7074; 1:5000
dilution) secondary antibodies at room temperature for 1
h. Protein bands were detected using ECL Plus Western
blotting substrate (Thermo Fisher) and ChemiDoc XRS+
imaging system (Bio-Rad).
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Table 3. Results of MYH9 and TUBB1 genomic DNA analysis.
MYH9 Variants

TUBB1 Variants

Found only in
patients

Found in
controls and
patients

Found only
in patients

Found in controls and
patients

Macrothrombocytopenia

-

-

-

c.803 G>T, c.920 G>A

-

c.821 C>T

c.803 G>T, c.920 G>A

PM2/PS3
PM2/PS3

ID

Sex

Clinical diagnosis

1

M

2

M

Macrothrombocytopenia

c.3756 C>A,
c.3762 G>A

3

F

Macrothrombocytopenia

-

-

c.821 C>T

c.803 G>T

4

M

Macrothrombocytopenia

-

c. 3660 T>G

-

c.803 G>T

5

M

Macrothrombocytopenia

-

-

-

c.803 G>T, c.920 G>A

6

M

Thrombocytopenia

c. 197 G>C

-

-

c.803 G>T, c.920 G>A

7

F

Macrothrombocytopenia

-

c. 3660 T>G

c.821 C>T

c.803 G>T, c.920 G>A

8

F

May Hegglin Anomaly

-

-

-

c.803 G>T

9

M

Macrothrombocytopenia

-

-

-

c.803 G>T

10

M

Thrombocytopenia

-

-

-

c.803 G>T

11

M

Macrothrombocytopenia

-

-

-

c.803 G>T, c.920 G>A

12

F

Thrombocytopenia

-

-

-

c.803 G>T, c.920 G>A

13

M

Macrothrombocytopenia

-

-

-

c.803 G>T, c.920 G>A

14

M

Macrothrombocytopenia

-

-

-

c.803 G>T, c.920 G>A

15

M

Thrombocytopenia

-

-

-

c.803 G>T

16

M

Macrothrombocytopenia

c. 286 T>G

-

-

c.803 G>T

17

M

Macrothrombocytopenia

-

-

c.636 C>G

c.803 G>T, c.920 G>A

18

M

May Hegglin Anomaly

-

-

-

c.803 G>T, c.920 G>A

19

M

Macrothrombocytopenia

c. 3814 T>G

-

-

c.803 G>T

20

M

Macrothrombocytopenia

-

-

-

c.803 G>T

21

F

Thrombocytopenia

-

-

-

c.803 G>T

22

M

Gray Platelet Syndrome

-

-

-

c.803 G>T, c.920 G>A

23

M

Thrombocytopenia

-

-

-

c.803 G>T

24

M

Thrombocytopenia

-

-

-

c.803 G>T, c.920 G>A

25

M

Macrothrombocytopenia

-

-

-

c.803 G>T

26

M

Macrothrombocytopenia

-

-

-

c.803 G>T

27

F

Macrothrombocytopenia

-

-

-

c.803 G>T, c.920 G>A

28

M

Macrothrombocytopenia

-

c. 3660 T>G

-

c.803 G>T

29

M

Macrothrombocytopenia

-

-

-

c.803 G>T, c.920 G>A

30

F

Macrothrombocytopenia

-

-

c.635 C>T

c.803 G>T, c.920 G>A

31

F

Thrombocytopenia

-

-

-

c.803 G>T

32

M

Macrothrombocytopenia

-

-

-

c.803 G>T

33

F

Thrombocytopenia

-

-

-

c.803 G>T, c.920 G>A

34

M

May Hegglin Anomaly

-

-

-

c.803 G>T

ACMG
classification

PM2/PS3

PM2/PS1

PM2/PS1

35

M

Thrombocytopenia

-

-

-

c.803 G>T

36

M

Thrombocytopenia

-

-

c.705 G>A

c.803 G>T, c.920 G>A

PM2/PS1

37

M

Thrombocytopenia

-

-

c.821 C>T

c.803 G>T, c.920 G>A

PM2/PS3
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2.6. Bioinformatic analysis
Computational mutation analysis was performed
using online prediction tools such as PROVEAN2,
MutationTaster23, and PolyPhen-24. MutationTaster2 was
also used for the multiple amino acid sequence alignment
of TUBB1 homologues.
3. Results
3.1. Sequencing of TUBB1 exons
Initially, we sequenced all of the exons (1 to 4) of TUBB1 in
patient samples (n = 37) to determine any possible TUBB1
2

http://provean.jcvi.org

3

http://www.mutationtaster.org

4

http://genetics.bwh.harvard.edu/pph2/

variant. Healthy controls (n = 47) were subsequently
sequenced to screen for TUBB1 variants that we found
in patient samples. All of the determined variants were
confirmed by repeating the corresponding PCR reactions
and using forward and reverse primers in the sequencing
analysis. Sequencing results of the patient samples did not
show any new variant in exons 1, 2, or 3 of TUBB1; however,
in exon-2 we found heterozygous TUBB1 variant c.130131 AG>CC (p.Q43P) in 4 patients (11%) and 7 healthy
controls (15%) (Figure 1A), which had been previously
reported as a functional polymorphism in congenital

Figure 1. Entire coding exons were amplified by PCR and sequenced. Heterozygous variations (A) c.130-131AG>CC (p.Q43P), (B)
c.803G>T (p.T178T), and (C) c.920G>A (p.R307H) were detected on TUBB1 gene from healthy controls and/or macrothrombocytopenia
patients by FinchTV sequence analysis software.
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macrothrombocytopenia patients [10]. Given that the
fourth exon of TUBB1 is the largest one (2950 base pairs)
and contains most of the published genetic variations [6],
we designed 6 different primer pairs to sequence this exon
(Table 1). Primer pairs, named exon 4.1 and 4.2 (Table
1), cover the coding region of the 4th exon. The TUBB1
variants described below were all covered within the PCR
products of the 4.1 and 4.2 primer pairs. In this region
of the 4th exon, we found a novel synonymous TUBB1
c.803G>T (p.T178T) variant in all of the healthy control
and patient samples (Figure 1B) (Table 3). In addition, we
showed previously-described TUBB1 variant c.920 G>A
(p.R307H) [11,12] for the first time in patients (19 out of 37;
51%) and healthy controls (13 out of 47; 28%) from Turkey
(Figure 1C) (Table 3). Importantly, we identified one new
silent (TUBB1 c.635C>T; p.H122H in patient #30) (Figure
2A) and 3 new heterozygous missense TUBB1 variants
in patient samples only (c.636C>G, p.E123Q in patient
#17; c.705G>A p.G146R in patient #36; and c.821C>T
p.T274M in patients #2, #3, #7, and #37) (Tables 2 and
3) (Figures 2B–2D). In the literature, the TUBB1 variant
T274M was associated with milder thrombocytopenia
in cancer patients treated with paclitaxel [13]; however,
to our knowledge, it was not previously described in
macrothrombocytopenia patients. The patients carrying
p.G146R, p.E123Q, and T274M were also positive for
the R307H variant. Two of the T274M carriers (Table 3;
patients #2 and #3) were relatives (a son and his mother,

respectively). We also showed that patients #2 and #7 are
carriers of TUBB1 variant c.920G>A (p.R307H) and MYH9
variants c.3756C>A (p.L1176M)/ c.3762G>A (p.E1182K)
and c.3660T>G (p.A1144L), respectively (Table 3); this
is the first presentation of the coexistence of the TUBB1
and MYH9 variants in macrothrombocytopenia patients.
Since we did not find TUBB1 variation in the remaining
portions of exon 4 in the patient samples (screened with
exon 4.3, 4.4, 4.5, and 4.6 primers), we did not screen these
regions of exon 4 in healthy control samples.
3.2. TUBB1 variant p. T274M/R307H changes the
microtubule structure
Due to sample limitations and the unavailability of other
patients carrying heterozygous missense mutations
(p.G146R and p.E123Q), we were able to clone and
analyze only the effect of TUBB1 variant p.T274M/
R307H (rs35565630/rs6070697) on the morphology
of the platelets of patient #7 and on the microtubule
organization of HeLa cells. The clinical data of patient #7
is summarized in Table 4. Both variants exist in the ExAC
database with high MAF values (p.T274M MAF value:
0.018 and p.R307H MAF value: 0.173). Computational
mutation analysis tools PROVEAN, MutationTaster2, and
PolyPhen-2 also predicted deleterious effects of p.T274M
variation on TUBB1 protein function (data not shown).
Endogenous TUBB1 mRNA was detectable in both the
peripheral blood mononuclear cells (PBMC) and plateletrich plasma samples of patient #7 (Figures 3A and 3B),

Figure 2. Sequencing also revealed heterozygous TUBB1 variations identified for the first time in macrothromboytopenia patients
in Turkish population. (A) A silent TUBB1 variation c.635C>T (p.H122H), and 3 missense variants (B) c.636C>G (p.E123Q), (C)
c.705G>A (p.G146R), and (D) c.821C>T (p.T274M) were detected in patient #30, patient #17, patient #36 and patients #2, #3, #7, and
#37, respectively.
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Figure 3. TUBB1 expression was detected in both mRNA and protein levels by using blood samples from healthy control (n=4, pooled)
and patient #7. RT-qPCR analysis showed relative TUBB1 gene expression in both (A) PBMC and (B) PRP fractions. All Taqman
assays were carried out in triplicates and relative fold change was calculated with the ΔΔCt method. (C) TUBB1 protein band was not
detectable in the whole lysate isolated from patient #7 contrary to healthy control.
Table 4. Clinical data of all patients carrying newly identified TUBB1 variants and patient #7 which is
proceeded for functional analysis.
Case

496

#2

#3

#7

#17

#30

#36

Age

21

13

13

12

4

14

Sex

Male

Male

Female

Male

Male

Female

WBC (103/ uL)

14.47

3.9

11.4

6.68

10.57

7.9

RBC (uL)

4.88

4.49

4.38

5.23

4.9

4.57

HB (g / dL )

14.3

11.9

11.4

13.6

11.6

12

HCT (%)

42.3

35

38.1

40.3

36.2

36.1

MCV (fL)

86.7

78.1

78.3

77.1

73.9

79.1

MCH (pg)

29.3

26.6

26.2

26

23.7

26.3

MCHC (g/dL)

33.8

34.1

32.8

33.7

32

33.3

PLT (103/ uL)

52

89

32

29

87

69

MPV (fL)

9.9

8.4

11.5

nd

13

9.6

PDW (fL)

12.2

17.1

13.6

nd

18.1

16

PCT (%)

0.05

0.074

0.04

nd

0.11

0.31

Consanguineous marriages

-

+

+

-

-

-

Bleeding problem

+

-

-

-

-

-

Renal disease

-

-

-

+

-

-

Cataracts

-

-

-

-

-

-

Hearing loss

-

-

-

-

-

-
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Figure 4. Peripheral blood smears were stained for marginal band detection in healthy or patient’s platelets. Endogenous TUBB1 and
α-Tubulin which are subunits of marginal band were marked with specific primary antibodies in combination with Alexa-555 (red) or
Alexa-488-conjugated (green) secondary antibodies, respectively. Marginal band was determined as a hollow-ring structure in healthy
platelets but circular microtubule arrangement was disappeared in patient #7’s platelets carrying TUBB1 variant p.T274M/R307H.
Merged images (yellowish) were captured in oiled 63X magnification by using LSM 880 (Zeiss) confocal microscope (upper panel).
Platelets labeled with an asterisk were zoomed in while image processing (bottom panel).

who is heterozygous for the variant p.T274M/R307H.
Although the endogenous TUBB1 protein was detectable
in the platelet samples of a healthy control, we could not
detect the TUBB1 protein in the platelets of patient #7
using Western blot analysis (Figure 3C). The IC analysis
of platelets by confocal microscopy showed a normal
marginal band structure (ring shaped) in a healthy control
sample; however, the marginal band was disrupted and
a diffuse staining with both α-TUBULIN and TUBB1
antibodies was observed in the majority of platelets from
the same patient (Figure 4). We also transiently expressed
the Flag-tagged TUBB1 variant p.T274M/R307H in the
HeLa cell line to determine its effect on microtubule
distribution under steady-state conditions. The IC analysis
of HeLa cells transfected with TUBB1 p.T274M/R307H
variant showed relatively diffuse cytoplasmic staining
with anti α-TUBULIN and anti-Flag antibodies (labels
the Flag-tagged TUBB1), whereas the control HeLa cells

transfected with wild type Flag-tagged TUBB1 showed a
more organized and clear microtubule net. These results
suggested that TUBB1-p.T274M/R307H variant causes
a disorganized microtubule structure under steady-state
conditions (Figure 5).
Interestingly, we also found the MYH9 (p.K64N)
and TUBB1 (p.R307H) variants in the same patient
(patient #7). While the variant in MYH9 causes a defect
in proplatelet formation and platelet secretion [14,15], an
understanding of the effects of the coexistence of these two
variants remains elusive.
4. Discussion
In the current study we screened all exons of the TUBB1
gene using DNA from the peripheral blood samples of
patients with macrothrombocytopenia from Turkey
(n = 37) (Table 3). The patients were selected based on
symptoms affecting platelet morphology, such as large
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Figure 5. IF analysis of HeLa cells transiently transfected with C-terminus Flag-tagged wild-type TUBB1 (WT) or T274M/R307H variant
constructs. Exogenous TUBB1 was labeled with anti-Flag primary antibody (Sigma-Aldrich, F7425; 1:100 dilution) and α-Tubulin was
labeled with anti-alpha Tubulin primary antibody (Santa Cruze, sc-5286; 1:100 dilution) in combination with Alexa-555 (red) or Alexa488-conjugated (green) secondary antibodies, respectively. Cells expressing WT protein have a branched microtubule organization but
transfection of T274M/R307H variant resulted in a disrupted and diffuse microtubule staining compared with WT and untransfected
cells. Successfully transfected and exogenous Flag-tagged TUBB1 expressing HeLa cells were labeled with an asterisk. Images were
captured in oiled 63X magnification by using LSM 880 (Zeiss) confocal microscope.

abnormal platelet structure, and the platelet count. We also
included DNA samples from healthy controls (n = 47).
We found 2 types of previously described TUBB1
polymorphisms (Q43P and R307H) for the first time
in Turkey. We also showed 3 new missense and 1
new silent variant in the fourth exon of TUBB1 in the
macrothrombocytopenia patients but not in healthy
controls (Table 2), which suggests that these are not
common polymorphisms. The findings are of great
importance, as they represent single nucleic acid base
changes which affect the amino acid sequences in the
protein. These changes can end up providing an abnormal
biochemical property, such as charge, hydrophobicity,
or size, within the wild type protein. To check this
theory, different function prediction programs such
as PROVEAN and Poly Phen-2 were utilized. Both
analyses suggest that the variants G146R and T274M have
potentially deleterious effects on TUBB1 (data not shown).
The p.G146R (the glycine in position 146 of β1‐tubulin)
is highly conserved, and the variation is located in the
amino‐terminal guanosine triphosphate domain of β1‐
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tubulin. In silico modeling confirmed its strong influence
on the structure of this domain, and the gene where this
mutation occurs is related to macrothrombocytopenia.
Reviewing TUBB1 and its genetic variations in
macrothrombocytopenia to date, we found that reported
mutations in mammals included 2 missense mutations,
p.R318W and p.F260S in exon 4 in humans [8,16], and
a missense mutation of p.D249N in canines [17]. All
of these variations are believed to be located in or near
the α- and β-tubulin intradimer interface, reportedly
causing macrothrombocytopenia in humans and dogs,
respectively. The intradimer interface of the platelet
structure is believed to be disrupted by these mutations,
causing frayed cytoskeleton formation and affecting
platelet morphology. With the exception of p.R307H
and p.Q43P polymorphisms, the variants discovered
in macrothrombocytopenia patients in our study are
distinct and do not overlap with earlier studies performed
in different populations, which suggests an evolutionary
difference in the Turkish population. Previously it was
shown that the ectopic expression of R307H variant in
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human MCF7 cells causes defects in microtubule regrowth
after treatment of the cells with nocodazole, a reagent
that depolymerizes the microtubules [18]. Given that it is
observed at high frequency in healthy individuals [27% in
our study (Tables 2 and 3) and 30% in Basciano et al.] [18],
it is likely that its effect on platelets is not disastrous. On
the other hand, although the p.T274M/R307H variant was
seen at a low frequency (0.023) in Caucasian populations
without a known history of macrothrombocytopenia, we
describe for the first time a tendency towards this variant
in macrothrombocytopenia patients (4 out of 37; 10%),
but not in healthy individuals from Turkey (n = 47); this
suggests a potential role for variant T274M/R307H in
the disturbed platelet structure that we observed in the
platelets of the patient sample (Figure 4). In support of our
hypothesis, Western blot analysis demonstrated that MCF7
cells express ectopic p.T274M or p.T274M/R307H, and
cancer patients carrying these variants are less sensitive
to the polymerization effect of paclitaxel on microtubules
[13]. Supporting these findings, we showed for the first
time that cytoplasmic distribution of the microtubule net
was disturbed under steady-state conditions in HeLa cells.
Although we were not able to functionally
link the variants p.G146R and p.E123Q to
macrothrombocytopenia, our data involving the T274M/
R307H variant suggest that it may be useful as a biomarker
in immune thrombocytopenia given its potential effect on
platelet turnover (which leads to lower platelet counts).
Finally, given that the synonymous TUBB1 p.T178T
variant was found in all of our healthy control and patient
samples, it is unlikely that this variant is associated with
macrothrombocytopenia.
The American College of Medical Genetics and
Genomics (ACMG) has recommended a five-tier

classification system [19]. According to this classification
system, a sequence change can be categorized as pathogenic,
likely pathogenic, uncertain significance, likely benign,
and benign. In our study, the p.705G>A, p.636C>G,
and p.821C>T variants were found only in patients, and
they had a small minor allele frequency (MAF) value,
suggesting their pathogenicity [nsv2778234 (ClinVar)].
Additionally, the variants that we found in 6 patients (#2,
#3, #7, #17, #30, and #36) could be categorized as PM2/
PS3 (pathogenic modified/pathogenic strong criteria).
Here, PM2 indicates that the mutation is found only in the
patient group and is absent in the controls; PS3 shows the
functional effect of mutation (Table 4).
In summary, our findings suggest that further
functional and clinical analyses of the new TUBB1
variants that we identified in macrothrombocytopenia
patients may provide new insights into the molecular
mechanisms of normal and abnormal platelet production
and morphology.
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